1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
MITECH Co., Ltd.

MITECH Co., Ltd.

KKRX:179290
4,275.00
KRW
+50.00
(+1.18%)
619.97EPS
6.96P/E
139.66BMarket Cap
Nov 18Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,893.69
945.07
1,213.95
1,069.61
1,308.03
1,608.88
1,755.79
1,442.64
1,660.58
2,073.93
2,139.15
Basic EPS, GAAP
847
86
16
120
217.36
392
598
398
565
628
619.97
Free Cash Flow per Basic Share
741.21
1.66
33.93
-72.75
22.91
489.15
247.1
524.3
695.23
306.11
-30.93
Dividend per Share
- -
- -
- -
49.82
49.49
59.89
77.76
119.72
79.77
99.96
- -
Book Value per Share
540.86
607.44
1,471.55
1,586.11
1,776.87
2,080.9
2,604.44
2,879.49
3,362.59
3,890.93
4,103.67
Tangible Book Value per Share
509.6
534.57
1,403.79
1,521.68
1,730.81
2,030.96
2,576.92
2,844.72
3,300.3
3,790.15
3,946.02
Basic Weighted Avg Shares
2
24
24
31
31
31
32
32
32
32
32
Sales/Revenue/Turnover
16,369
22,541
29,599
32,655
40,203
50,259
56,220
46,387
53,753
67,152
69,205
Operating Margin (%)
12.99
9.68
17.09
10.32
16.18
26.28
39.64
30.32
32.7
30.79
29.66
Depreciation Expense
783
933
1,052
1,556
2,052
2,212
2,145
1,850
1,841
2,501
2,361
Net Income, GAAP
2,011
2,051
390
3,664
6,681
12,245
19,148
12,798
18,289
20,334
20,057
Effective Tax Rate (%)
- -
- -
64.07
0.28
15.02
15.41
15.65
15.78
18.22
18.13
14.22
Profit Margin (%)
12.29
9.1
1.32
11.22
16.62
24.36
34.06
27.59
34.02
30.28
28.98
Working Capital
10,083
14,933
37,935
28,372
35,531
42,114
67,368
72,936
82,074
70,925
90,220
LT Debt
- -
4,200
- -
591
2,313
1,647
537
379
298
5,543
5,270
Total Equity
16,628
18,677
44,768
48,262
55,404
64,761
83,548
92,937
108,833
125,932
132,818
Return on Invested Capital (%)
- -
- -
5.52
7.03
9.75
16.79
23.81
13.15
14.05
13.83
13.84
Return on Capital (%)
- -
- -
1.55
7.68
11.88
18.6
24.58
14.32
18.04
16.92
16.01
Return on Common Equity (%)
- -
11.62
1.23
7.88
12.89
20.38
25.82
14.5
18.13
17.32
16.43

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Mar'26
Jun'26
ST Debt
1,293
1,374
1,496
LT Borrowings
- -
- -
- -
LT Finance Leases
4,219
5,378
5,270
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
222,352
220,087
139,658

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Mar'26
Jun'26
Total Current Assets
81,863
84,876
102,948
Cash, Cash Equivalents & STI
56,305
56,403
65,799
Accounts Receivable, Net
11,016
12,768
18,921
Inventories
13,226
13,644
15,938
Total Current Liabilities
8,635
12,678
12,728
Payables & Accruals
- -
- -
- -
ST Debt
1,293
1,374
1,496
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
17.99%
15.71%
Free Cash Flow
- -
422.41%
-55.96%
Net Income, GAAP
- -
32.12%
11.18%
Sales/Revenue/Turnover
- -
12.04%
24.93%
Total Cash Common Dividend
- -
20.62%
25.35%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,269
12,803
15,442
12,239
53,753
2025
17,249
15,666
17,059
- -
67,152
2026
16,728
19,752
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
174
147
135
109.59
565
2025
179
138
152.74
- -
628
2026
149.19
180
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
79.77
2025
- -
- -
- -
- -
99.96
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jae-Oh Kwak
Full Time Employees
179
Sector
Health technology
Industry
Medical specialties
Address
Pyeongtaek-si South Korea
IPO Date
Nov 29, 2018
Website
mitech.co.kr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
M.I.Tech Co., Ltd. is a South Korea-based medical device manufacturer specializing in the development, production, and distribution of non-vascular interventional medical devices and therapeutic equipment. Founded in 1991 and headquartered in Pyeongtaek, South Korea, the company serves hospitals, medical centers, and distributors across domestic and international markets spanning Asia, Europe, North America, and Latin America. M.I.Tech operates primarily within the interventional gastroenterology, pulmonology, and urology sectors. Its core product offerings are organized into specialized categories, including non-vascular self-expanding metallic stents marketed under the HANAROSTENT brand; esophageal stents designed for palliative treatment of malignant and benign strictures; biliary and pancreatic stents for relieving ductal obstructions; duodenal and colorectal stents for gastrointestinal stenosis decompression; tracheobronchial stents for airway maintenance; endoscopic intervention accessories including biliary guide wires, extraction balloons, dilation catheters, biopsy forceps, and retrieval baskets; extracorporeal shock wave lithotripsy systems for the non-invasive fragmentation of renal and urinary calculi; and extracorporeal shock wave therapy devices for musculoskeletal rehabilitation and pain management. In recent strategic developments, the company has broadened its global market penetration through expanded international commercial distribution partnerships with multinational medical technology corporations across major overseas markets, including North America, Europe, and Japan. In addition, M.I.Tech has advanced its regulatory compliance and product lifecycle by securing European Medical Device Regulation certifications and international clearances, while expanding its research, development, and manufacturing capabilities in next-generation biodegradable stent platforms and drug-eluting non-vascular technologies.